In this article we will discuss Ramucirumab (27)
Category: Ramucirumab
In this article, we will discuss Ramucirumab (26). So, let’s get started. Use in Specific Population Pregn*ncy Category C Risk Summary Based on its mechanism of action, Ramucirumab may cause fetal harm. Animal models link angiogenesis, VEGF and VEGF Receptor 2 (VEGFR2) to critical aspects of female reproduction, embryo-fetal development, and post-natal development. There are […]
In this article we will discuss Ramucirumab (25). So, let’s get started. Immunogenicity As with all therapeutic proteins, there is the potential for immunogenicity. In clinical trials, 53/884 (6%) of Ramucirumab-treated patients with post baseline serum samples tested positive for treatment-emergent anti-ramucirumab antibodies by an enzyme-linked immunosorbent assay (ELISA). However, this assay has limitations in […]
In this article, we will discuss Ramucirumab (24). So, let’s get started. Clinical Trials Experience (4) Ramucirumab Administered in Combination with Paclitaxel Among 327 patients who received Ramucirumab (safety population) in Study 2, median age was 60 years, 31% were women, 63% were W Hite, and 33% were Asian. Patients in Study 2 received a […]
In this article, we will discuss Ramucirumab (23). So, let’s get started. Clinical Trials Experience (3) Across clinical trials of Ramucirumab administered as a single agent, clinically relevant adverse reactions (including Grade ≥3) reported in Ramucirumab-treated patients included proteinuria, gastrointestinal perforation, and infusion-related reactions. In Study 1, according to laboratory assessment, 8% of Ramucirumab-treated patients […]
In this article, we will discuss Ramucirumab (22). So, let’s get started. Clinical Trials Experience (3) Clinically relevant adverse reactions reported in ≥1% and <5% of Ramucirumab-treated patients in Study 1 were: neutropenia (4.7% Ramucirumab versus 0.9% placebo), epistaxis (4.7% Ramucirumab versus 0.9% placebo), rash (4.2% Ramucirumab versus 1.7% placebo), intestinal obstruction (2.1% Ramucirumab versus […]